Table 2: Pathologic findings in patients <71 years and ≥71 years.

Pathologic finding <71 years ≥71 years value

Histopathology
 Infiltrating ductal1408 (68%)265 (69%)0.028
 Infiltrating lobular164 (7.9%)45 (12%)
 Ductal carcinoma in situ424 (21%)66 (17%)
 Unknown69 (3.3%)6 (1.6%)
Tumor differentiation
 Well319 (15%)60 (17%)0.000
 Moderately855 (41%)207 (54%)
 Poorly650 (31%)84 (22%)
 Unknown241 (12%)31 (8.1%)
Tumor size (cm)*
 Median1.41.20.015
 0–21428 (69%)276 (72%)0.250
 2.1–5398 (19%)75 (20%)
 >5.1117 (6%)14 (3.7%)
 Unknown122 (6%)17 (4.5%)
Node positive486/1524 (32%)61/249 (25%)0.027
Involved nodes
 Mean3.93.70.705
 01137 (69%)201 (76%)0.066
 1–3320 (20%)37 (14%)
 4+180 (11%)26 (10%)
Estrogen receptor positive1314/1702 (77%)275/321 (86%)<0.001
Initial resection margin: close/involved751/1898 (40%)225/353 (64%)<0.001
Final Margin: close/involved134/1863 (7.2%)43/344 (13%)0.002
Examined nodes (mean)6.95.70.002
Axillary node sampling1524/1572 (97%)249/310 (80%)<0.001
Surgery
 Breast conservation1529 (74%)327 (86%)<0.001
 Mastectomy519 (25%)55 (14%)
 Unknown17 (0.8%)0 (0%)
Neoadjuvant chemotherapy280/1572 (18%)20/310 (6.4%)<0.001
Postoperative chemotherapy517/1572 (33%)23/310 (7.2)<0.001
Tamoxifen/aromatase Inhibitor 1011/1809 (56%)244/364 (67%)<0.001
Tamoxifen among estrogen receptor positive patients912/1217 (75%)214/273 (78%)0.231
Radiation therapy1328/1442 (92%)184/365 (50%)<0.001
Radiation therapy in breast conservation 1232/1529 (81%)173/327 (53%)<0.001

Data are presented as or (%). (*Size of invasive component. Invasive tumors).